We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


EnzymenRx Lauches Clinical Study of Uricase-PEG 20

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "EnzymenRx Lauches Clinical Study of Uricase-PEG 20"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
EnzymeRx, LLC has announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.

Last month, EnzymeRx announced that its Investigational New Drug application for intravenous Uricase-PEG 20 had become effective. EnzymeRx is pursuing the development of Uricase-PEG 20 as an intravenous agent for the management of elevated uric acid associated with tumor lysis syndrome, and as an intramuscular agent for the treatment of refractory gout.

Tony Fiorino, MD, PhD, President and Chief Executive Officer of EnzymeRx, remarked: “Our team has worked very diligently with the study sites and with Kendle to launch this clinical trial after receiving FDA clearance last month. Sites are screening potential enrollees, and several subjects have already received Uricase-PEG 20.”

John Bomalaski, MD, Chief Medical Officer of EnzymeRx, added: “It is gratifying to see Uricase-PEG 20 back in the clinic. This study will provide important information on the safety, tolerability, pharmacokinetics and uric acid lowering capacity of Uricase-PEG 20 administered intravenously, and will allow us to proceed to future development in tumor lysis syndrome.”

Gout and tumor lysis syndrome are both associated with elevated levels of uric acid. Tumor lysis syndrome is a serious condition that can occur during the treatment of certain tumors, and can result in sharply elevated uric acid levels. Uricase-PEG 20 metabolizes poorly soluble uric acid into highly soluble allantoin, and in a prior phase 1 clinical trial, it was shown to lower uric acid levels in gout patients.